Erenumab: from scientific evidence to clinical practice-the first Italian real-life data

Neurol Sci. 2019 May;40(Suppl 1):177-179. doi: 10.1007/s10072-019-03839-x.

Authors

Piero Barbanti^{1

2}, Cinzia Aurilia³, Gabriella Egeo³, Luisa Fofi³

Affiliations

¹ Headache and Pain Unit, Department of Neurological, Motor and Sensorial Sciences, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163, Rome, Italy. piero.barbanti@sanraffaele.it.
² San Raffaele University, Rome, Italy. piero.barbanti@sanraffaele.it.
³ Headache and Pain Unit, Department of Neurological, Motor and Sensorial Sciences, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163, Rome, Italy.

PMID: 30927136
DOI: 10.1007/s10072-019-03839-x

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Calcitonin Gene-Related Peptide Receptor Antagonists / therapeutic use*
Humans
Italy
Migraine Disorders / prevention & control*

Substances

Antibodies, Monoclonal, Humanized
Calcitonin Gene-Related Peptide Receptor Antagonists
erenumab